Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials

Brierley, 2017 Antonia, 2017, Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer, N Engl J Med, 377, 1919, 10.1056/NEJMoa1709937 Faivre-Finn, 2021, Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC-an update from the PACIFIC trial, J Thorac Oncol, 16, 860, 10.1016/j.jtho.2020.12.015 Betticher, 2003, Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial, J Clin Oncol, 21, 1752, 10.1200/JCO.2003.11.040 Stupp, 2009, Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial, Lancet Oncol, 10, 785, 10.1016/S1470-2045(09)70172-X Pless, 2015, Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial, Lancet, 386, 1049, 10.1016/S0140-6736(15)60294-X Curioni-Fontecedro, 2019, Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08), Br J Cancer, 120, 968, 10.1038/s41416-019-0447-0 Rothschild, 2021, SAKK 16/14: durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small-cell lung cancer-a multicenter single-arm phase II trial, J Clin Oncol, JCO2100276 Forde, 2018, Neoadjuvant PD-1 blockade in resectable lung cancer, N Engl J Med, 378, 1976, 10.1056/NEJMoa1716078 Shu, 2020, Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial, Lancet Oncol, 21, 786, 10.1016/S1470-2045(20)30140-6 Rothschild, 2020, SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—a multicenter single-arm phase II trial, J Clin Oncol, 38, 9016, 10.1200/JCO.2020.38.15_suppl.9016 Provencio, 2020, Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial, Lancet Oncol, 21, 10.1016/S1470-2045(20)30453-8 Spicer, 2021, Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC), J Clin Oncol, 39, 8503, 10.1200/JCO.2021.39.15_suppl.8503 Wakelee, 2021, IMpower010: primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC), J Clin Oncol, 39, 8500, 10.1200/JCO.2021.39.15_suppl.8500 Fruh, 2019, Multimodal treatment in operable stage III NSCLC: a pooled analysis on long-term results of three SAKK trials (SAKK 16/96, 16/00, and 16/01), J Thorac Oncol, 14, 115, 10.1016/j.jtho.2018.09.011 Eberhardt, 2013, Lung Cancer, 82, 83, 10.1016/j.lungcan.2013.06.007 Martini, 1995, Mediastinal lymph node dissection for lung cancer. The Memorial experience, Chest Surg Clin N Am, 5, 189 Katakami, 2012, A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903), Cancer, 118, 6126, 10.1002/cncr.26689 Pottgen, 2015, Prognostic model for long-term survival of locally advanced non-small-cell lung cancer patients after neoadjuvant radiochemotherapy and resection integrating clinical and histopathologic factors, BMC Cancer, 15, 363, 10.1186/s12885-015-1389-4 Eberhardt, 2015, Phase III study of surgery versus definitive concurrent chemoradiotherapy boost in patients with resectable stage IIIA(N2) and selected IIIB non-small-cell lung cancer after induction chemotherapy and concurrent chemoradiotherapy (ESPATUE), J Clin Oncol, 33, 4194, 10.1200/JCO.2015.62.6812 Bradley, 2020, Long-term results of NRG oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer, J Clin Oncol, 38, 706, 10.1200/JCO.19.01162 Rosell, 1994, A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer, N Engl J Med, 330, 153, 10.1056/NEJM199401203300301 Johnstone, 2002, Int J Radiat Oncol Biol Phys, 54, 365, 10.1016/S0360-3016(02)02943-7 Stephens, 2005, Medical Research Council Lung Cancer Working Party. A randomised controlled trial of pre-operative chemotherapy followed, if feasible, by resection versus radiotherapy in patients with inoperable stage T3, N1, M0 or T1-3, N2, M0 non-small cell lung cancer, Lung Cancer, 49, 395, 10.1016/j.lungcan.2005.04.001 Albain, 2009, Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial, Lancet, 374, 379, 10.1016/S0140-6736(09)60737-6 van Meerbeeck, 2007, Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer, J Natl Cancer Inst, 99, 442, 10.1093/jnci/djk093 Thomas, 2008, Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer, Lancet Oncol, 9, 636, 10.1016/S1470-2045(08)70156-6